Please assess the completion status of the following clinical trial:

Trial Title: Effect of Oral Administration of a Herbarium Mixture (Guazuma Ulmifolia and Tecoma Stans) on Metabolic Profile in Type 2 Diabetic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signing of letter of consent under written information.~* Men and women with serum glucose of ≥126 and \<400 mg / dl and / or HbA1c ≥6.5% and \<10%.~* Age between 30 and 60 years.~* BMI between 25 - 39.9 kg / m2.~* With or without pharmacological treatment with oral hypoglycemic agents or insulin~* Stable body weight during the last 3 months (± 5%).~* Women in the follicular phase of the menstrual cycle (days 3 to 8 of the cycle) at the time of the laboratory tests~* Women who do not expect to be pregnant within the next 3 months.~Exclusion Criteria:~* Physical or mental incapacity that makes it impossible to carry out the intervention.~* Uncontrolled thyroid disease~* Women with suspicion or confirmation of pregnancy.~* Women who are breastfeeding.~* Hepatic disease or elevation to double the upper normal value of TGO and TGP.~* Diagnosis of renal insufficiency or creatinine\> 1.5 mg / dL or glomerular filtration rate \<60 mL / min).~* Known hypersensitivity to calcined magnesia or Guazuma ulmifolia and / or Tecoma stans.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): The patients were randomly assigned to received placebo (calcinaned magnesia), 1 capsule before each meal for a period of 90 days.
- Guazuma ulmifolia plus Tecoma stans (Type: EXPERIMENTAL): The patients were randomly assigned to received the herbarium mixture (GU/TS) , 1 capsule of 400mg, before each meal for a period of 90 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).